Published

Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Psychiatry research
Date: 2025-10-01
Source: PubMed
DOI: 10.1016/j.psychres.2025.116697
PubMed: 40840197

Authors

Rosa I Padula LP Semeraro F Marrangone C Inserra A De Risio L Boffa M Zoratto F Borgi M Guidotti R Lorenzo GD D'Addario C Pettorruso M Martinotti G

Watch author

Derived topics and classifications

psilocybin Depression Mechanism of Action Receptor Pharmacology Review Article Animal Study Treatment-Resistant Depression Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions.2025-10-01

Related papers

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.ClinicalTrials.gov · 2025-09-10 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30 Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled TrialClinicalTrials.gov · 2026-05-07 Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)ClinicalTrials.gov · 2025-10-07 Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?Research Directions Depression · 2023-10-13 Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant DepressionClinicalTrials.gov · 2022-05-20